Considerations for the prediction of survival time in pancreatic cancer based on registry data

被引:1
|
作者
Bajaj, Gaurav [1 ]
Dombrowsky, Erin [1 ]
Yu, Qilu [2 ]
Agarwal, Banke [3 ]
Barrett, Jeffrey S. [1 ]
机构
[1] Childrens Hosp Philadelphia, Lab Appl PK PD, Dept Clin Pharmacol & Therapeut, Philadelphia, PA 19104 USA
[2] Westat Corp, Rockville, MD USA
[3] St Louis Univ, Dept Gastroenterol, St Louis, MO 63103 USA
关键词
Pancreatic cancer; SEER; Survival prediction; Registry data; DOSE RATE GEMCITABINE; TUMOR SIZE; PHASE-II; ADENOCARCINOMA; COMBINATION; CISPLATIN; ONCOLOGY; DESIGN; MODELS; STILL;
D O I
10.1007/s10928-013-9327-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Semi-parametric and parametric survival models in patients with pancreatic adenocarcinoma (PC) using data from Surveillance, Epidemiology, and End Result (SEER) registry were developed to identify relevant covariates affecting survival, verify against external patient data and predict disease outcome. Data from 82,251 patients was extracted using site and histology codes for PC in the SEER database and refined based on specific cause of death. Predictors affecting survival were selected from SEER database; the analysis dataset included 2,437 patients. Survival models were developed using both semi-parametric and parametric approaches, evaluated using Cox-Snell and deviance residuals, and predictions were assessed using an external dataset from Saint Louis University (SLU). Prediction error curves (PECs) were used to evaluate prediction performance of these models compared to Kaplan-Meier response. Median overall survival time of patients from SEER data was 5 months. Our analysis shows that the PC data from SEER was best fitted by both semi-parametric and the parametric model with log-logistic distribution. Predictors that influence survival included disease stage, grade, histology, tumor size, radiation, chemotherapy, surgery, and lymph node status. Survival time predictions from the SLU dataset were comparable and PECs show that both semi-parametric and parametric models exhibit similar predictive performance. PC survival models constructed from registry data can provide a means to classify patients into risk-based subgroups, to predict disease outcome and aide in the design of future prospective randomized trials. These models can evolve to incorporate predictive biomarker and pharmacogenetic correlates once adequate causal data is established.
引用
收藏
页码:527 / 536
页数:10
相关论文
共 50 条
  • [31] Differences in cancer survival by remoteness of residence: an analysis of data from a population-based cancer registry
    Afshar, Nina
    English, Dallas R.
    Chamberlain, James A.
    Blakely, Tony
    Thursfield, Vicky
    Farrugia, Helen
    Giles, Graham G.
    Milne, Roger L.
    CANCER CAUSES & CONTROL, 2020, 31 (07) : 617 - 629
  • [32] The Incidence and Survival Rate of Population-Based Pancreatic Cancer Patients: Shanghai Cancer Registry 2004-2009
    Luo, Jianfeng
    Xiao, Linhai
    Wu, Chunxiao
    Zheng, Ying
    Zhao, Naiqing
    PLOS ONE, 2013, 8 (10):
  • [33] Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data
    Ito, Yuri
    Miyashiro, Isao
    Ito, Hidemi
    Hosono, Satoyo
    Chihara, Dai
    Nakata-Yamada, Kayo
    Nakayama, Masashi
    Matsuzaka, Masashi
    Hattori, Masakazu
    Sugiyama, Hiromi
    Oze, Isao
    Tanaka, Rina
    Nomura, Etsuko
    Nishino, Yoshikazu
    Matsuda, Tomohiro
    Ioka, Akiko
    Tsukuma, Hideaki
    Nakayama, Tomio
    CANCER SCIENCE, 2014, 105 (11) : 1480 - 1486
  • [34] Terminal cancer:: duration and prediction of survival time
    Llobera, J
    Esteva, M
    Rifà, J
    Benito, E
    Terrasa, J
    Rojas, C
    Pons, O
    Catalán, G
    Avellà, A
    EUROPEAN JOURNAL OF CANCER, 2000, 36 (16) : 2036 - 2043
  • [35] Integration of RNA-Seq and RPPA data for survival time prediction in cancer patients
    Isik, Zerrin
    Ercan, Muserref Ece
    COMPUTERS IN BIOLOGY AND MEDICINE, 2017, 89 : 397 - 404
  • [36] Epidemiological research - cancer registry data. Survival time analysis - comparison of national and international results
    Brenner, Hermann
    Weberpals, Janick
    Jansen, Lina
    ONKOLOGE, 2017, 23 (04): : 272 - 279
  • [37] Pancreatic Cancer Survival Prediction: A Survey of the State-of-the-Art
    Bakasa, Wilson
    Viriri, Serestina
    COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE, 2021, 2021
  • [38] A DNA Methylation Signature to Improve Survival Prediction of Pancreatic Cancer
    Qu, D.
    Wu, X.
    Chandrakesan, P.
    Houchen, C. W.
    PANCREAS, 2020, 49 (10) : 1425 - 1425
  • [39] Development and Validation of a Survival Prediction Model for Patients With Pancreatic Cancer
    James, Paul D.
    Almousawi, Fatema
    Salim, Misbah
    Khan, Rishad
    Tanuseputro, Peter
    Hsu, Amy T.
    Coburn, Natalie
    Alabdulkarim, Balqis
    Talarico, Robert
    Gayowsky, Anastasia
    Webber, Colleen
    Seow, Hsien
    Sutradhar, Rinku
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2025, 16 (01)
  • [40] Pancreatic cancer survival prediction via inflammatory serum markers
    Lanki, Mira
    Seppanen, Hanna
    Mustonen, Harri
    Salmiheimo, Aino
    Stenman, Ulf-Hakan
    Salmi, Marko
    Jalkanen, Sirpa
    Haglund, Caj
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (09) : 2287 - 2292